In this video interview with SOHO Insider, Guillermo García-Manero, MD, professor and chief of the Section of Myelodysplastic Syndromes and ad interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, presents phase 2 results from the ASTX030-01 trial, which is evaluating ASTX030, an investigational oral azacitidine–cedazuridine (140/20 mg) formulation, in patients with MDS, CMML, MDS/MPN overlap syndromes, and AML who are candidates for single-agent azacitidine.
Dr. García-Manero discusses how oral azacitidine-cedazuridine compares to injected hypomethylating agents, including clinical activity, tolerability, and BSA-adjusted dosing for the ongoing phase 3 trial.
Reference
Garcia-Manero G, Borate U, Brunner A. A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Abstract #491. Presented at 2025 American Society of Hematology Annual Meeting. December 6–9; Orlando, FL.
